We quickly evaluated and selected two potent, complementary antibodies that bound to different, non-overlapping parts of the spike protein of the SARS-CoV-2 virus, thereby blocking the virus's ability to infect healthy cells.

At Regeneron, we've identified bottlenecks in the drug discovery and development process, and developed VelociSuite, our own toolkit of innovative technologies, to address them. Our technologies provide a greater chance of producing effective medicines that benefit human health.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies, as well as bispecific and costimulatory antibodies.

We invent and research potential new medicines for a broad range of serious conditions, including retinal eye diseases, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

Regeneron Reviews FAQs Is Regeneron a good company to work for? Regeneron has an overall rating of 3.9 out of 5, based on over 1,857 reviews left anonymously by employees. 69% of employees would recommend working at Regeneron to a friend and 77% have a positive outlook for the business.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies, as well as bispecific and costimulatory antibodies.

Our 2025 responsibility goals span our three strategic focus areas: improving the lives of people with serious diseases, fostering a culture of integrity and excellence and building sustainable communities.

Regeneron Pharmaceuticals

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.

Net sales of Libtayo, which is a top selling product of Regeneron Pharmaceuticals, amounted to nearly 448 million dollars in 2022. In the year before, the top selling drug for Regeneron was COVID-19 treatment Regen-COV, generating sales of some 5.8 billion U.S. dollars.

For 35 years, our mission has been to use the power of science to bring new medicines to patients… over and over again. Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases.

REGN Stock 12 Months Forecast Based on 16 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $908.13 with a high forecast of $1,050.00 and a low forecast of $680.00. The average price target represents a 8.55% change from the last price of $836.57.